The FDA-approved only gene therapy for Duchenne muscular dystrophy is costing far too much for families to afford. Families simply cannot afford this prohibitive price. Manufacturers should reconsider the price of DMD gene therapies. According to an announcement by Genethon on January 23, the collaboration with Eukarÿs could bring the price of DMD gene therapies down to a reasonable level.
Today, Eukarÿs, a biotechnology firm creating a game-changing technology that dramatically boosts biomanufacturing yields, and Genethon, a pioneer and leader in the research and development of gene treatments for rare diseases, announced the formation of a strategic agreement. The collaboration uses Eukarÿs’ unique C3P3 technology, a novel messenger RNA (mRNA) expression method in mammalian cells, to lower the cost of producing gene therapy medications.
Learn More: Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
Read More: Frequently Asked Questions About Elevidys